Patents by Inventor David Bodmer
David Bodmer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150218223Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.Type: ApplicationFiled: April 8, 2015Publication date: August 6, 2015Applicant: Novartis AGInventors: Rainer Albert, Wilfried Bauer, David Bodmer, Christian Bruns, Ivo Felner, Heribert Hellstern, Ian Lewis, Mark Meisenbach, Gisbert Weckbecker, Bernhard Wietfeld
-
Patent number: 9035021Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.Type: GrantFiled: March 16, 2011Date of Patent: May 19, 2015Assignee: Novartis AGInventors: Rainer Albert, Wilfried Bauer, David Bodmer, Christian Bruns, Ivo Felner, Heribert Hellstern, Ian Lewis, Mark Meisenbach, Gisbert Weckbecker, Bernhard Wietfeld
-
Patent number: 8822637Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O-)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.Type: GrantFiled: March 16, 2011Date of Patent: September 2, 2014Assignee: Novartis AGInventors: Rainer Albert, Wilfried Bauer, David Bodmer, Christian Bruns, Ivo Felner, Heribert Hellstern, Ian Lewis, Mark Meisenbach, Gisbert Weckbecker, Bernhard Wietfeld
-
Publication number: 20120269894Abstract: The present invention relates to ophthalmic depot formulations comprising an active agent, e.g. embedded in a pharmacologically acceptable biocompatible polymer or a lipid encapsulating agent, e.g. for periocular or subconjunctival administration.Type: ApplicationFiled: June 14, 2012Publication date: October 25, 2012Inventors: Marklus AHLHEIM, Michael AUSBORN, David BODMER, Christian SCHOCH
-
Publication number: 20110172157Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.Type: ApplicationFiled: March 16, 2011Publication date: July 14, 2011Applicant: NOVARTIS AGInventors: Rainer Albert, Wilfried Bauer, David Bodmer, Christian Bruns, Ivo Felner, Heribert Hellstern, Ian Lewis, Mark Meisenbach, Gisbert Weckbecker, Bernhard Wietfeld
-
Publication number: 20110166320Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.Type: ApplicationFiled: March 16, 2011Publication date: July 7, 2011Applicant: NOVARTIS AGInventors: Rainer Albert, Wilfried Bauer, David Bodmer, Christian Bruns, Ivo Felner, Heribert Hellstern, Ian Lewis, Mark Meisenbach, Gisbert Weckbecker, Bernhard Wietfeld
-
Patent number: 7939625Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.Type: GrantFiled: November 5, 2008Date of Patent: May 10, 2011Assignee: Novartis AGInventors: Rainer Albert, Wilfried Bauer, David Bodmer, Christian Bruns, Ivo Felner, Heribert Hellstern, Ian Lewis, Mark Meisenbach, Gisbert Weckbecker, Bernhard Wietfeld
-
Publication number: 20090069225Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.Type: ApplicationFiled: November 5, 2008Publication date: March 12, 2009Applicant: NOVARTIS AGInventors: Rainer Albert, Wilfried Bauer, David Bodmer, Christian Bruns, Ivo Felner, Heribert Hellstern, Ian Lewis, Mark Meisenbach, Gisbert Weckbecker, Bernhard Wietfeld
-
Patent number: 7473761Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.Type: GrantFiled: July 30, 2001Date of Patent: January 6, 2009Assignee: Novartis AGInventors: Rainer Albert, Wilfried Bauer, David Bodmer, Christian Bruns, Ivo Felner, Heribert Hellstern, Ian Lewis, Mark Meisenbach, Gisbert Weckbecker, Bernhard Wietfeld
-
Publication number: 20080305172Abstract: The present invention relates to ophthalmic depot formulations comprising an active agent, e.g. embedded in a pharmacologically acceptable biocompatible polymer or a lipid encapsulating agent, e.g. for periocular or subconjunctival administration.Type: ApplicationFiled: August 20, 2008Publication date: December 11, 2008Inventors: Marklus Ahlheim, Michael Ausborn, David Bodmer, Christian Schoch
-
Publication number: 20050014686Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.Type: ApplicationFiled: July 30, 2001Publication date: January 20, 2005Inventors: Rainer Albert, Wlifried Bauer, David Bodmer, Christian Bruns, Ivo Felner, Heribert Hellstern, Ian Lewis, Mark Meissenbach, Gisbert Weckbecker, Bernhard Wietfeld
-
Publication number: 20040234611Abstract: The present invention relates to ophthalmic depot formulations comprising an active agent, e.g. embedded in a pharmacologically acceptable biocompatible polymer or a lipid encapsulating agent, e.g. for periocular or subconjunctival administration.Type: ApplicationFiled: March 12, 2004Publication date: November 25, 2004Inventors: Marklus Ahlheim, Michael Ausborn, David Bodmer, Christian Schoch
-
Patent number: 6623753Abstract: The invention concerns liposomal preparations comprising as the active agent a compound of formula I in free base form or in acid addition salt form. It also concerns a method of preparation of such liposomal preparations by encapsulating a compound of formula I with an appropriate liposome forming material, a corresponding pharmaceutical compositions, and methods of treatment of systemic, topical and pulmonal fungal infections.Type: GrantFiled: June 24, 1997Date of Patent: September 23, 2003Assignee: Novartis AGInventors: David Bodmer, Thomas Kissel, Friedrich Richter, Harry Tiemessen
-
Patent number: 6262127Abstract: This invention provides pharmaceutical compositions comprising polymeric matrices, especially those comprising IL-6 as an active ingredient. Specific novel poly(ethylene carbomate) polymers are also provided for more general use as matrix materials in sustained release compositions containing pharmacologically active compounds, as are methods of using of IL-6 for treatment of conditions mediated by IL-1 and/or TNF&agr;, e.g., certain autoimmune and inflammatory conditions, as well as septic shock.Type: GrantFiled: July 20, 1999Date of Patent: July 17, 2001Assignee: Novartis AGInventors: Murat Acemoglu, Siegfried Bantle, David Bodmer, Salvatore Cammisuli, Peter Hiestand, Fritz Nimmerfall, Georg Stoll
-
Patent number: 6204308Abstract: An emulsion-based method of microencapsulating an active agent wherein a water-in-oil emulsion, containing a matrix-forming polymer and an active agent, is dispersed in an aqueous external phase to form a microencapsulated product.Type: GrantFiled: March 1, 1999Date of Patent: March 20, 2001Assignee: Novartis AGInventors: Michael Ausborn, David Bodmer, Oskar Nagele, Laurent Marchal
-
Patent number: 6083521Abstract: This invention provides pharmaceutical compositions comprising polymeric matrices, especially those comprising IL-6 as an active ingredient. Specific novel poly(ethylene carbomate) polymers are also provided for more general use as matrix materials in sustained release compositions containing pharmacologically active compounds, as are methods of using of IL-6 for treatment of conditions mediated by IL-1 and/or TNF.alpha., e.g., certain autoimmune and inflammatory conditions, as well as septic shock.Type: GrantFiled: September 28, 1998Date of Patent: July 4, 2000Assignee: Novartis AGInventors: Murat Acemoglu, Siegfried Bantle, David Bodmer, Salvatore Cammisuli, Peter Hiestand, Fritz Nimmerfall, Georg Stoll
-
Patent number: 5876761Abstract: The invention discloses microparticles comprising a polypeptide, preferably somatostatin or an analog or derivative thereof, more preferably octreotide, in a polymeric matrix, preferably poly(lactide-co-glycolide) glucose. The invention also discloses sustained release formulations containing said microparticles and the use of said formulations in treating acromegaly and breast cancer.Type: GrantFiled: June 6, 1995Date of Patent: March 2, 1999Assignee: Novartis AGInventors: David Bodmer, Jones W. Fong, Thomas Kissel, Hawkins V. Maulding, Oskar Nagele, Jane E. Pearson
-
Patent number: 5688530Abstract: The invention discloses microparticles comprising a polypeptide, preferably somatostatin or an analog or derivative thereof, more preferably octreotide, in a polymeric matrix, preferably poly(lactide-co-glycolide) glucose. The invention also discloses sustained release formulations containing said microparticles and the use of said formulations in treating acromegaly and breast cancer.Type: GrantFiled: June 6, 1995Date of Patent: November 18, 1997Assignee: Novartis AGInventors: David Bodmer, Jones W. Fong, Thomas Kissel, Hawkins V. Maulding, Oskar Nagele, Jane E. Pearson
-
Patent number: 5639480Abstract: The invention discloses microparticles comprising a polypeptide, preferably somatostatin or an analog or derivative thereof, more preferably octreotide, in a polymeric matrix, preferably poly(lactide-co-glycolide)glucose. The invention also discloses sustained release formulations containing said microparticles and the use of said formulations in treating acromegaly and breast cancer.Type: GrantFiled: June 6, 1995Date of Patent: June 17, 1997Assignee: Sandoz Ltd.Inventors: David Bodmer, Jones W. Fong, Thomas Kissel, Hawkins V. Maulding, Oskar Nagele, Jane E. Pearson
-
Patent number: 5538739Abstract: The invention discloses microparticles comprising a polypeptide, preferably somatostatin or an analog or derivative thereof, more preferably octreotide, in a polymeric matrix, preferably poly(lactide-co-glycolide) glucose. The invention also discloses sustained release formulations containing said microparticles and the use of said formulations in treating acromegaly and breast cancer.Type: GrantFiled: January 18, 1991Date of Patent: July 23, 1996Assignee: Sandoz Ltd.Inventors: David Bodmer, Jones W. Fong, Thomas Kissel, Hawkins V. Maulding, Jr., Oskar Nagele, Jane E. Pearson
-
Patent number: 5260280Abstract: Sialic acid binding proteins, sialic acid-binding peptides and sialic acid containing oligo-saccharides are active ingredients of a novel bacterial enterotoxin neutralizer and interfere with the binding of enterotoxins, including cholera toxin, to receptors so as to exert an effect of neutralizing the toxicity, thus being utilized as an effective neutralizer and are safe and available cheaply and abundantly from by-products produced during the processing of cow's milk which renders the enterotoxin neutralizer economically advantageous for commercial use.Type: GrantFiled: July 14, 1992Date of Patent: November 9, 1993Assignee: Snow Brand Milk Products Co., Ltd.Inventors: Hiroko Isoda, Yoshihiro Kawasaki, Morimasa Tanimoto, Shunichi Dosako, Tadashi Idota